Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen. The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”. After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4. Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

FilterHomeInhibitory Antibodies
  • Tocilizumab
    T9911375823-41-9
    Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor
    • $223
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Rituximab
    T9910174722-31-7
    Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.
    • $229
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Infliximab
    T9921170277-31-3
    Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
    • $98
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Cetuximab
    T9905205923-56-4
    Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
    • $197
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Etanercept
    T37445185243-69-0
    Etanercept is a dimeric fusion protein that serves as a competitive TNF inhibitor by binding to TNF. It effectively inhibits the binding of both TNF-α and TNF-β to the TNF receptors on cell surfaces, thereby rendering TNF biologically inactive. Etanercept has demonstrated efficacy in treating rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
    • $328
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Bevacizumab
    T9904216974-75-3
    Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.
    • $129
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Teneliximab
    T76830299423-37-3
    Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.
    • $247
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Evolocumab
    T99201256937-27-5
    Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
    • $397
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Pembrolizumab
    T99081374853-91-4
    Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.
    • $218
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Nivolumab
    T9907946414-94-4
    Nivolumab (anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1PD-1PCD-1) with immune checkpoint inhibitory and antineoplastic activities.
    • $182
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Adalimumab
    T9901331731-18-1
    Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
    • $213
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Trastuzumab
    T9912180288-69-1
    Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
    • $157
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Atezolizumab
    T99021380723-44-3
    Atezolizumab (anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
    • $229
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Zilovertamab
    T767491643432-38-5
    Zilovertamab (UC-961) is a humanized anti-ROR1 monoclonal antibody that cuts off the WNT5A-induced ROR1 signaling pathway and shows anti-proliferative activity in ovarian and endometrial cancer cells. It can be used to study lymphatic cancer.
    • $247
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Gemtuzumab
    T9901A-0032924764-21-4
    Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.
    • $282
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Ensituximab
    T774071092658-06-4
    Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.
    • $189
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Burfiralimab
    T769372460809-80-5
    Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) directed against waveform proteins that has anti-HBV effects and can be used to study rheumatoid arthritis,
    • $197
    In Stock
    Size
    QTY
  • Ipilimumab
    T9906477202-00-9
    Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
    • $456
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Anti-Mouse PD-1 Antibody (RMP1-14)
    T78269
    RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.
    • $99
    In Stock
    Size
    QTY
  • Brolucizumab
    T805931531589-13-5
    Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment exhibiting low picomolar affinity (K D = 1.05 pM), utilized for cancer research [1] [2].
    • $247
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Ormutivimab
    T805942449086-91-1
    Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Davoceticept
    T805982307144-64-3
    Davoceticept (ALPN-202; CD80 vIgD-Fc), a monoclonal antibody that targets CTLA-4, is comprised of the (1-107) fragment of CD80 fused to the IGHG1 Fc domain through a peptidyl linker. It is commonly produced in CHO (Chinese Hamster Ovary) cells [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Peginterferon lambda-1a
    T80600914617-98-4
    Peginterferon lambda-1a (BMS-914143) is a monoclonal antibody that targets IFNLR1 and is composed of IFNL1 conjugated to pegol [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Dresbuxelimab
    T806032550560-20-6
    Dresbuxelimab (AK-119), an IgG-κ monoclonal antibody, selectively targets CD73 and is commonly produced using a Chinese Hamster Ovary (CHO) cell expression system [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Eblasakimab
    T806072445460-16-0
    Eblasakimab (also known as ASLAN004 or CSL-334) is a human IgG4 monoclonal antibody that selectively binds to IL13RA1, and is predominantly produced in CHO-K1 cells [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Romilkimab
    T806101399584-78-1
    Romilkimab (SAR156597) is a chimeric humanized immunoglobulin (Ig) antibody designed to specifically target interleukins 4 and 13 (IL-4 and IL-13) [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Linvoseltamab
    T806132408319-25-3
    Linvoseltamab, a bispecific antibody, targets both BCMA (TNFRSF17) and CD3 epsilon, demonstrating a favorable safety profile and promising efficacy in relapsed/refractory multiple myeloma (RRMM) [1][2].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Vixtimotamab
    T80858
    Vixtimotamab (AMV-564; TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively engages human CD33 and CD3 antigens. It is utilized in research on acute myeloid leukemia (AML) [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Adecatumumab
    T77747503605-66-1
    Adecatumumab (MT201) is a whole-person IgG1 monoclonal antibody to human EpCAM. Adecatumumab has potential anticancer activity and can be used to study breast cancer.
    • $289
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Rocatinlimab
    T783332431972-52-8
    Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated IgG1 anti-OX40 monoclonal antibody indicated for atopic dermatitis (AD) research [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Aselizumab
    T78301395639-53-9
    Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody (mAb) targeting L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils that directs cell migration through chemotaxis to injury sites. Notably, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma [1] [2].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Anti-Mouse PD-L1 Antibody (10F.9G2)
    T78270
    Anti-Mouse PD-L1 Antibody is a rat-derived IgG2b monoclonal antibody that inhibits mouse PD-L1.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Ligelizumab
    T782891322627-61-1
    Ligelizumab (QGE 031), a high-affinity humanized monoclonal anti-IgE antibody, is utilized in the research of chronic spontaneous urticaria [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Epcoritamab
    T783312134641-34-0
    Epcoritamab (GEN3013) is a bispecific IgG1 antibody that redirects T-cells toward CD3×CD20-positive tumor cells, inducing potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Sulesomab
    T81070167747-19-5
    Sulesomab (IMMU-MN3), an IgG1 class murine monoclonal antibody fragment, targets the Normal Cross-Reactive Antigen-90 found on leukocytes. The compound nonspecifically accumulates at infection sites due to enhanced permeability of capillary membranes [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Verzistobart
    T808682649466-18-0
    Verzistobart, an IgG1κ antibody, specifically targets the hepatitis A virus cellular receptor, HAVCR2.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Vatelizumab
    T808751238217-55-4
    Vatelizumab (GBR500), a monoclonal antibody, specifically targets the α2 subunit (CD49b) of very late antigen-2 (VLA-2) and is utilized in multiple sclerosis research [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Unasnemab
    T80900
    Unasnemab (MT-3921), a humanized IgG1 monoclonal antibody, targets repulsive guidance molecule A (RGMa) to enhance locomotor function and support neuroregeneration, showing potential for spinal cord injury research [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Stapokibart
    T810982734715-10-5
    Stapokibart (CM310), a humanized monoclonal antibody, selectively binds to IL-4Rα, inhibiting the cytokines IL-4 and IL-13 from interacting with their shared co-receptor subunit, IL-4Rα. This compound demonstrates cross-species reactivity by interacting with IL-4Rα in humans, cynomolgus monkeys, and rats [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Ralzapastotug
    T813122581724-89-0
    Ralzapastotug (AB-308) is a monoclonal antibody that targets amino acids 106-126 of the prion protein PrP^C[1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Perenostobart
    T815102643331-31-9
    Perenostobart, a humanized IgG4-κ monoclonal antibody targeting ENTPD1/CD39, serves as both an immunostimulant and an antineoplastic [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Palsucibep pegol
    T815602218524-43-5
    Palsucibep pegol is an engineered protein that specifically binds to human lipocalin-2. It also targets hepcidin [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Osemitamab
    T815942460539-61-9
    Osemitamab, an IgG1 antibody, targets human claudin-18.2 and comprises a human-Mus musculus monoclonal TST001 γ1-chain disulfide-bonded to a human-Mus musculus monoclonal TST001 κ-chain dimer (ACI). It is utilized, in conjunction with Capecitabine and Oxaliplatin, for gastric/gastroesophageal junction (G/GEJ) cancer studies [1] [2].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Peginterferon alfacon-2
    T815281848968-91-1
    Peginterferon alfacon-2 is a human antibody that targets IFNAR1/2 [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Mouse IgG3 kappa, Isotype Control
    T81756
    Mouse IgG3 kappa Isotype Control is a monoclonal antibody serving as an isotype control specifically for mouse IgG3κ antibodies.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Lixudebart
    T819252749515-10-2
    Lixudebart is a humanized IgG1-kappa monoclonal antibody that targets CLDN1 [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Lorukafusp alfa
    T819172131168-99-3
    Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine composed of the humanized 14.18 anti-GD2 monoclonal antibody (mAb) connected to interleukin-2 (IL210). It exerts its anti-tumor effects [1] through the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity. This is achieved by the targeted binding of hu14.18-IL2 to GD2-expressing tumor cells, which facilitates subsequent interaction with Fc receptors on immune effector cells, as well as the stimulation of natural killer (NK) and T cells through their IL2 receptors.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Human IgG1 (D265A) kappa, Isotype Control
    T82161
    Human IgG1 (D265A) kappa Isotype Control is a chimeric monoclonal antibody derived from both human and mouse, designed to serve as an isotype control for the human IgG1 (D265A)κ antibody.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Human IgG1 lambda1, Isotype Control
    T82157
    Human IgG1 lambda1 Isotype Control is a chimeric human-mouse monoclonal antibody serving as an isotype control for human IgG1λ1 antibody.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Grisnilimab
    T822602367001-70-3
    Grisnilimab (WT1), an IgG2a monoclonal antibody targeting CD7, acts as a tumor suppressor in the pathogenesis of Wilms' tumor. It modulates the transcription of various genes and may be involved in post-transcriptional RNA processing [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale